Prospective study on identification of predictors of effect of omalizumab on seasonal allergic rhinitis in clinical practice
Not Applicable
Recruiting
- Conditions
- Seasonal allergic rhinitis bronchial asthma chronic urticaria
- Registration Number
- JPRN-UMIN000039245
- Lead Sponsor
- Japanese Red Cross Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with serious complications such as heart disease, liver disease, and renal disorder 2) Other patients who are judged inappropriate by the doctor
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Predictors of patients with improved nasal symptom score 12 weeks after omalizumab administration compared to peak symptoms
- Secondary Outcome Measures
Name Time Method 1. Percentage of patients with improved nasal symptom score 12 weeks after omalizumab administration compared to peak symptoms. 2. To identify the percentage of patients whose ocular symptom score improved 12 weeks after administration of omalizumab compared to the peak symptom period and to identify predictors of the improvement. 3. To identify the percentage of patients who improved their WPAI-AS score 12 weeks after omalizumab administration compared to the peak period of symptoms and to identify predictors. 4. Therapeutic effects of complications (such as asthma and chronic urticaria) 5. The incidence of Grade 1 or higher adverse events during omalizumab treatment.